Squarepoint’s Fibrocell Science Inc. FCSC Stock Holding History

Squarepoint’s Portfolio FCSC Stock Details FCSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-2,220	Closed	-$38K	–	1380
2016 Q2	$38K	Buy	+2,220	New	+$69.1K	﹤0.01%	1043

Other funds holding FCSC

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Squarepoint's FCSC Position: Q3 2016 in Review

Squarepoint sold out of Fibrocell Science Inc. (FCSC) in Q3 2016, closing a stake of 2,220 shares — an estimated $38K sold.

Squarepoint first reported a position in FCSC in Q2 2016 and held it in 1 quarter. The position peaked at $38K in Q2 2016. 37 funds tracked by Wall St. Rank hold FCSC as of Q3 2016.

Squarepoint reported no remaining Fibrocell Science Inc. position as of Q3 2016 after selling out during the quarter.
Squarepoint sold 2,220 Fibrocell Science Inc. shares in Q3 2016, an estimated $38K.
Squarepoint first reported a position in Fibrocell Science Inc. in Q2 2016 and held it in 1 quarter.
Squarepoint's Fibrocell Science Inc. position peaked at $38K in Q2 2016.
37 funds tracked by Wall St. Rank held Fibrocell Science Inc. as of Q3 2016.

Based on Squarepoint's 13F filing for Q3 2016, filed 15 Nov 2016.